Jazz Pharmaceuticals presented new Phase 4 and real-world data at SLEEP 2026 showing Xywav’s cardiometabolic benefits and feasibility of personalized dosing in narcolepsy and idiopathic hypersomnia.
Written By: Kirti Kumbhar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
Jazz Pharmaceuticals unveiled 11 late-breaking presentations at SLEEP 2026, strengthening the clinical profile of Xywav® (calcium, magnesium, potassium, and sodium oxybates). The findings highlight the therapy’s potential benefits beyond symptom control, including improvements in cardiometabolic health and support for individualized dosing strategies.
Clinical Context
Narcolepsy and idiopathic hypersomnia are chronic neurological sleep disorders characterized by excessive daytime sleepiness, disrupted sleep architecture, and impaired daily functioning. Patients with narcolepsy face elevated risks of hypertension, stroke, myocardial infarction, and heart failure, making cardiovascular health an important component of long-term disease management.
Xywav is the only low-sodium oxybate approved in the United States for the treatment of cataplexy or excessive daytime sleepiness in patients aged seven years and older with narcolepsy and for idiopathic hypersomnia in adults. Compared with traditional high-sodium oxybate therapies,
Xywav reduces nightly sodium exposure by approximately 1,000 to 1,500 mg. This reduction may be particularly relevant for patients who require lifelong treatment and already face increased cardiovascular risk.
Trial and Real-World Data
New analyses from the Phase 4 DUET study (NCT05875974) demonstrated that individualized dose titration supported both once-nightly and twice-nightly treatment regimens based on patient response and tolerability. Patients reached stable dosing after a mean of approximately 42 days in both narcolepsy and idiopathic hypersomnia cohorts.
Complementary data from the FDA-mandated Xywav Risk Evaluation and Mitigation Strategy (REMS) program, encompassing more than 13,000 patients, confirmed the practical feasibility of personalized dosing in routine clinical practice and provided additional real-world evidence supporting individualized treatment approaches.
Cardiometabolic Outcomes
Secondary analyses from the Phase 4 XYLO study (NCT05869773) showed that patients switching from high-sodium oxybate to Xywav reported improvements in sodium-related symptoms such as edema, nocturia, and excessive sweating.
A retrospective electronic health record analysis further revealed reductions in non-HDL cholesterol and triglycerides, alongside lower systolic blood pressure and increased HDL cholesterol in patients transitioning from high-sodium oxybate. These findings suggest that patients may retain the established benefits of oxybate therapy while potentially reducing the cardiometabolic burden associated with chronic sodium exposure.
Clinical Implications
Logan Schneider, M.D., adjunct clinical associate professor of sleep medicine at Stanford Sleep Center and consultant neurologist at the Stanford/VA Alzheimer’s Center emphasized that effective management of narcolepsy and idiopathic hypersomnia extends beyond symptom reduction. The emerging evidence highlights the importance of cardiovascular health in conditions that often require lifelong therapy.
Jessa Alexander, Ph.D., neuroscience therapeutic area head of Global Medical and Scientific Affairs at Jazz Pharmaceuticals noted that the REMS data and emerging cardiometabolic findings continue to strengthen understanding of Xywav’s long-term clinical profile and its potential role in supporting broader patient health outcomes.
Implications for Practice
The SLEEP 2026 presentations expand the evidence base supporting Xywav’s role in rare sleep disorders. Ongoing research will further examine how sodium reduction influences sleep architecture, patient-reported outcomes, and cardiometabolic health.
As clinicians increasingly adopt personalized treatment strategies, the integration of clinical trial and real-world evidence may help refine long-term management approaches for patients living with narcolepsy and idiopathic hypersomnia.
What This Means for Patients
For people living with narcolepsy or idiopathic hypersomnia, treatment goals extend beyond staying awake during the day. Many require lifelong therapy and face elevated risks of cardiovascular complications such as hypertension and heart disease.
The SLEEP 2026 findings suggest that Xywav’s low-sodium formulation may deliver benefits beyond symptom control. Patients switching from high-sodium oxybate reported improvements in sodium-related symptoms such as edema and nocturia, while researchers observed favorable changes in cardiometabolic markers including cholesterol, triglycerides, and blood pressure.
The data also highlight dosing flexibility. Individualized titration allowed once- or twice-nightly regimens tailored to patient response and tolerability, supporting treatment schedules that better align with daily routines and sleep patterns.
With REMS oversight ensuring safe use, these results reinforce that reducing sodium exposure may support long-term health while maintaining the established efficacy of oxybate therapy in managing narcolepsy and idiopathic hypersomnia.
Reference
About the Writer
Kirti Kumbhar (LinkedIn) is an M.Pharm graduate with experience in Quality Assurance at Lupin Limited and a strong interest in clinical research, regulatory affairs, and Trial Master File (TMF) management. She has developed knowledge of regulatory documentation, quality systems, compliance, and healthcare research through her professional experience. Passionate about clinical development and continuous learning, Kirti is committed to supporting high-quality healthcare documentation, regulatory excellence, and research-driven healthcare advancements.